NCT07730021

A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2026-08-31Est. Completion: 2030-02-28

Enrollment target: 392 participants

Contact

Astellas Pharma Global Development, Inc.Astellas.registration@astellas.com 800-888-7704

Other microbiome trials you might be interested in

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyPhase 2Recruiting

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell CarcinomaLocally Recurrent Laryngeal Squamous Cell CarcinomaLocally Recurrent Oral Cavity Squamous Cell CarcinomaLocally Recurrent Oropharyngeal Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.